Report for Ligueros-Saylan M

General

Full name :

First name :

Mail :

Zip Code :

City :

Country :

Email :

Phone :

Fax :

Website :

Directory :

References (8)

Title : An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials - Ligueros-Saylan_2010_Diabetes.Obes.Metab_12_495
Author(s) : Ligueros-Saylan M , Foley JE , Schweizer A , Couturier A , Kothny W
Ref : Diabetes Obes Metab , 12 :495 , 2010
Abstract : Ligueros-Saylan_2010_Diabetes.Obes.Metab_12_495
ESTHER : Ligueros-Saylan_2010_Diabetes.Obes.Metab_12_495
PubMedSearch : Ligueros-Saylan_2010_Diabetes.Obes.Metab_12_495
PubMedID: 20518805

Title : Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes - Azuma_2008_J.Clin.Endocrinol.Metab_93_459
Author(s) : Azuma K , Radikova Z , Mancino J , Toledo FG , Thomas E , Kangani C , Dalla Man C , Cobelli C , Holst JJ , Deacon CF , He Y , Ligueros-Saylan M , Serra D , Foley JE , Kelley DE
Ref : J Clinical Endocrinology Metab , 93 :459 , 2008
Abstract : Azuma_2008_J.Clin.Endocrinol.Metab_93_459
ESTHER : Azuma_2008_J.Clin.Endocrinol.Metab_93_459
PubMedSearch : Azuma_2008_J.Clin.Endocrinol.Metab_93_459
PubMedID: 18042650

Title : Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes - Serra_2008_Int.J.Clin.Pharmacol.Ther_46_349
Author(s) : Serra D , He YL , Bullock J , Riviere GJ , Balez S , Schwartz S , Wang Y , Ligueros-Saylan M , Jarugula V , Dole WP
Ref : Int J Clinical Pharmacology & Therapeutics , 46 :349 , 2008
Abstract : Serra_2008_Int.J.Clin.Pharmacol.Ther_46_349
ESTHER : Serra_2008_Int.J.Clin.Pharmacol.Ther_46_349
PubMedSearch : Serra_2008_Int.J.Clin.Pharmacol.Ther_46_349
PubMedID: 18793589

Title : Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects - He_2008_J.Clin.Pharmacol_48_85
Author(s) : He YL , Ligueros-Saylan M , Sunkara G , Sabo R , Zhao C , Wang Y , Campestrini J , Pommier F , Dole K , Marion A , Dole WP , Howard D
Ref : Journal of Clinical Pharmacology , 48 :85 , 2008
Abstract : He_2008_J.Clin.Pharmacol_48_85
ESTHER : He_2008_J.Clin.Pharmacol_48_85
PubMedSearch : He_2008_J.Clin.Pharmacol_48_85
PubMedID: 17986525

Title : The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients - Balas_2007_J.Clin.Endocrinol.Metab_92_1249
Author(s) : Balas B , Baig MR , Watson C , Dunning BE , Ligueros-Saylan M , Wang Y , He YL , Darland C , Holst JJ , Deacon CF , Cusi K , Mari A , Foley JE , DeFronzo RA
Ref : J Clinical Endocrinology Metab , 92 :1249 , 2007
Abstract : Balas_2007_J.Clin.Endocrinol.Metab_92_1249
ESTHER : Balas_2007_J.Clin.Endocrinol.Metab_92_1249
PubMedSearch : Balas_2007_J.Clin.Endocrinol.Metab_92_1249
PubMedID: 17244786

Title : The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin - He_2007_Eur.J.Clin.Pharmacol_63_677
Author(s) : He YL , Sabo R , Campestrini J , Wang Y , Ligueros-Saylan M , Lasseter KC , Dilzer SC , Howard D , Dole WP
Ref : European Journal of Clinical Pharmacology , 63 :677 , 2007
Abstract : He_2007_Eur.J.Clin.Pharmacol_63_677
ESTHER : He_2007_Eur.J.Clin.Pharmacol_63_677
PubMedSearch : He_2007_Eur.J.Clin.Pharmacol_63_677
PubMedID: 17486328

Title : Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects - He_2007_Curr.Med.Res.Opin_23_1131
Author(s) : He YL , Sabo R , Riviere GJ , Sunkara G , Leon S , Ligueros-Saylan M , Rosenberg M , Dole WP , Howard D
Ref : Curr Med Res Opin , 23 :1131 , 2007
Abstract : He_2007_Curr.Med.Res.Opin_23_1131
ESTHER : He_2007_Curr.Med.Res.Opin_23_1131
PubMedSearch : He_2007_Curr.Med.Res.Opin_23_1131
PubMedID: 17519080

Title : Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes - Mari_2005_J.Clin.Endocrinol.Metab_90_4888
Author(s) : Mari A , Sallas WM , He YL , Watson C , Ligueros-Saylan M , Dunning BE , Deacon CF , Holst JJ , Foley JE
Ref : J Clinical Endocrinology Metab , 90 :4888 , 2005
Abstract : Mari_2005_J.Clin.Endocrinol.Metab_90_4888
ESTHER : Mari_2005_J.Clin.Endocrinol.Metab_90_4888
PubMedSearch : Mari_2005_J.Clin.Endocrinol.Metab_90_4888
PubMedID: 15886245